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Abstract
Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants.
Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F). A
novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a number of escape mutants for three known
inhibitors of RSV-F that have been isolated. Homology modeling of the RSV-F structure has been carried out on the basis of a chimera
derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus
(NDV). The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to
specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters. The positions of the
characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Respiratory syncytial virus (RSV) is the predominant cause
of acute lower respiratory tract infection in children, with
symptoms ranging from severe pneumonia and bronchiolitis to
much milder infections similar to the common cold (Cane,
2001, Collins et al., 1996). While primary infection does gen-
erate a long-term immune response this is not fully protective
and recurrent infection can occur throughout life, with annual
reinfection rates of 3–6% in adults (Monto and Lim, 1971).
RSV infection is also a major cause of morbidity and mortality
in institutionalized elderly and immunocompromised adults
(Collins et al., 1996).
RSV is a member of the Pneumovirus genus of the
family Paramyxoviridae, which includes other human
pathogens such as mumps, measles, and the parainfluenza
viruses. The RSV genome is a single strand of negative-
sense RNA encoding 10 proteins. Three viral proteins, G, F,
and SH, are located on the surface of infected cells and
virions. While G and SH are believed to play a significant
role in attachment and entry, the F glycoprotein is necessary
and sufficient for viral infection and the fusion of infected
cells with their neighbors to form syncytia (Kahn et al.,
1999; Techaarpornkul et al., 2001).
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RSV-F is expressed as a single precursor of 574 amino
acids, F0, which oligomerizes in the endoplasmic reticulum
and is proteolytically processed at two sites in each mono-
mer, resulting in an oligomer of two disulfide-linked frag-
ments: F2 (the smaller N-terminal fragment) and F1. The
protein is anchored in membranes through a hydrophobic
peptide in the C-terminal region of F1 which is followed by
a 24-amino-acid cytoplasmic tail. The protein is also gly-
cosylated at five or six potential N-linked sites located
principally in F2 and contains palmitate (Collins et al.,
1996). RSV-F is believed to adopt a metastable prefuso-
genic conformation until triggered in the presence of a
target membrane and/or receptor. Triggering of the protein
is thought to result in a conformational change that exposes
a very hydrophobic stretch of residues at the extreme N
terminus of F1, known as the fusion peptide. It is generally
believed that the fusion peptide associates with the target
cell membrane on exposure. In this model, the change from
the prefusogenic structure to the final fusogenic conforma-
tion of the protein brings the fusion peptide into close
proximity to the anchor sequence, promoting the fusion of
the virus (and/or infected cell) membrane with the target
cell membrane.
The structure of a fragment of the fusion protein of
Newcastle disease virus (NDV) has been reported at a
resolution of 3.3 Å (Chen et al., 2001). This protein has
some similarity in both sequence and mode of action to the
RSV fusion protein. Only 355 of the 553 residues in the
NDV fusion protein were present in the final crystal form
(residues 33–105 and 171–454), such that important regions
of the protein structure were absent. Another structure was
subsequently reported for the core fragment of RSV-F itself
(Zhao et al., 2000) which included a large section of the
protein absent from the NDV-F structure.
We report herein a novel syncytium formation assay for
activity of recombinant RSV-F expressed from an opti-
mized gene construct that allows rapid in vitro assessment
of fusion inhibitors and the analysis of resistance mutations.
We also describe the structure of the majority of the RSV-F
protein produced by molecular modeling on the basis of a
chimera devised by combining the fragmentary NDV-F
crystal structure with the structure of the RSV-F core. We
have employed this model as a tool to reach a greater
understanding of the mechanism of action of RSV-F inhib-
itors and the nature of known sites of neutralizing antibody
binding.
Results and discussion
Syncytium formation assay using recombinant RSV-F in
mammalian cells
Initial attempts to express RSV-F using viral cDNA
fragments derived from RT-PCR of viral mRNA were un-
successful. Constructs designed to express either the full-
length version of F or a soluble version of F lacking the
transmembrane and cytoplasmic regions failed to elicit sig-
nificant expression when tested in transient assays in 293
cells. Reasons for low expression could include: the high
percentage of rare codons present in the RSV-F coding
region, the presence of multiple poly-(A) addition se-
quences, and the presence of splice acceptor and donor sites
within the coding region. A synthetic RSV-F construct was
therefore assembled incorporating optimized codon usage
and with potential poly-(A) and splice sites removed (Ma-
son et al., 2000). The construct also incorporated multiple
unique restriction sites to simplify subsequent mutagenesis
studies.
Analysis of expression of both the soluble and trans-
membrane synthetic F constructs showed that RSV-F ex-
pression levels improved by at least 20- to 50-fold com-
pared with RSV-F natural sequence vectors (data not
shown). Although recent reports have indicated that RSV-F
is sufficient to support viral entry (Techaarpornkul et al.,
2001) and induce syncytium formation in a vesicular sto-
matitis virus background (Kahn et al., 1999), previous re-
ports have shown that RSV-F, -G, and -SH are required for
efficient fusion when vaccinia virus vectors are used (Hem-
inway et al., 1994). The possible contribution of other viral
proteins derived from RSV or the viral expression systems
to F function in these systems has not been elucidated.
Extensive syncytium formation was observed 48 h post-
transfection of just the synthetic F construct into 293 cells
(Fig. 1A), indicating that F alone is sufficient for membrane
fusion. In contrast, 293 cells transfected under identical
conditions with an equivalent plasmid expressing RSV A2 F
natural codon sequence (Fig. 1B) appeared similar to the
mock-transfected control (Fig. 1C). In addition, we ob-
served that the size and extent of syncytium formation in
293 cells expressing F from the synthetic gene were unaf-
fected by coexpression of codon-optimized constructs for
RSV-G or RSV-SH, neither of which initiate syncytium
formation when expressed alone (Heminway et al., 1994)
and that known fusion inhibitors prevented syncytium for-
mation in a concentration-dependent manner (Fig. 2, Table
1). To our knowledge, this is the first demonstration of
cellular fusion mediated by RSV-F in the absence of any
other viral proteins, and provides an assay system for anal-
ysis of RSV-F inhibitors and mutants that is free of the
confounding variables that may potentially be introduced by
coexpression of other viral gene products.
Identification of RSV-F escape mutants
A combination of serial passage and the syncytium for-
mation assay was used to identify RSV-F inhibitor escape
mutants. Three published RSV-F inhibitors were used to
raise inhibitor-resistance mutant viruses. Escape mutants for
each compound (Fig. 3: compound 1: VP14637 Viropharma
Inc., Patent WO 99/38508; compound 2: R170591, Jannsen
Pharmaceutica, Patent WO 01/00612; compound 3: CL-
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387626, Wyeth–Ayerst Research (Wyde et al., 1998)) were
isolated by serial passage of the virus in the presence of the
inhibitor (Table 2). The F genes of resistant viruses were
sequenced and the sites of mutation identified.
A total of nine distinct escape mutations across eight
different resistant isolates were characterized for the three
compounds tested (Table 2). Two distinct sets of mutation
hotspots were identified: one corresponding to resistance to
compounds 1 and 2, the other to escape from inhibition by
compound 3. As these data show, compounds 1 and 2, while
structurally dissimilar, gave rise to very similar resistance
mutations and showed cross-sensitivity, in that mutations
identified as giving resistance to compound 1 also gave rise
to equivalent resistance to compound 2 and vice versa. All
mutations identified in the resistant isolates were analysed
in the syncytium formation assay to confirm that they were
responsible for the observed inhibitor resistance (Table 1).
A selection of the scoring data for one of the resistance
mutants is shown graphically in Fig. 4 to highlight the
clarity of results from the assay.
Recombinant F protein expression and electron
microscopy
While providing adequate expression levels of RSV-F
for assay purposes, the yield of protein in the mammalian
expression system was too low for any detailed structural
studies. To generate high levels of the F glycoprotein for
analysis, we constructed a recombinant baculovirus that
expressed a secreted form of F in which the transmembrane
and cytoplasmic tail domains were replaced by a C-terminal
six-histidine tag. The recombinant RSV-F was purified from
infected culture medium harvests by Ni2- affinity chroma-
tography and analyzed by SDS-PAGE (Fig. 5A). Overex-
pression of the wild-type RSV A2 F sequence in this system
always yielded two species migrating with molecular
weights of approximately 72 and 62 kDa (1 and 2 respec-
tively in Fig. 5A). Analysis under reducing conditions re-
vealed that these species comprised disulfide-bonded frag-
ments and a variable amount (depending on the preparation)
of uncleaved F0. N-terminal sequencing of the resulting 50-
and 46-kDa fragments (Fig. 5A, F1 and F1, respectively)
revealed that cleavage of the F0 precursor had occurred at
two independent sites. Site 1 cleavage (133RKRR/FLGF140)
generated the expected F1 fragment reported for RSV F (46
kDa) but a second cleavage site (106RARR/ELPR113), N
terminal to a stretch of amino acids unique to RSV-F,
generated the additional fragment F1. We subsequently
confirmed that this second cleavage site was essential for
fusion activation (Mason et al., 2000) as has subsequently been
shown by others (Gonzalez-Reyes et al., 2001; Zimmer et al.,
2001). Endoglycosidase digestions further showed that the F2
fragments of 19 and 16 kDa were glycosylation variants, most
likely comprising carbohydrate moieties at two and one of the
available sites, respectively. A schematic summary of these
findings is presented in Fig. 5B.
Recombinant RSV-F purified from baculovirus vector-
infected culture supernatants was examined by electron mi-
croscopy to determine gross characteristics of protein struc-
ture (Fig. 5C). In agreement with work reported by others
(Calder et al., 2000; Gonzalez-Reyes et al., 2001), two
different RSV-F conformations were observed, previously
described as “cones” and “lollipops,” which may corre-
spond to prefusogenic and fusogenic structures of the pro-
Fig. 1. Formation of syncytia in cell cultures transfected with expression
plasmids for RSV-F constructs. Transfection with plasmid expressing the
codon-optimized RSV-F construct pCICO.F.FL.opt (A) causes substan-
tially greater levels of syncytium formation compared with transfection
with wild-type RSV-F (B). Mock-transfected cells show no syncytium
formation and remain confluent (C). In all cases photographs were taken of
cells 48 h posttransfection at 400 magnification.
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tein. Both single trimeric species (mostly “cones”) and
rosettes (comprising mostly “lollipops”) can be seen in
these preparations. This is the first demonstration of high-
level expression of recombinant RSV-F and demonstrates
that the overall morphology and processing of the recom-
binant protein are the same as found in native expression.
Molecular modeling
The model structure for the postfusion conformation of
residues 29 to 98 and 160 to 515 of RSV-F is shown in Fig.
6 with details of the alignment between the RSV-F and
NDV-F sequences and secondary structure predictions used
to build the model. The excellent agreement between the
predicted secondary structure for RSV-F and NDV-F and
the experimental secondary structure derived from the
NDV-F crystal increases confidence in the accuracy of the
model despite the rather low level of sequence identity
between the two proteins. The RSV-F protein consists of a
trimer of disulfide-linked F2–F1 pairs arranged with three-
fold symmetry about a central axis. As described in the
published work detailing the structure of the related viral
fusion protein NDV-F (Chen et al., 2001), the protein can be
divided on inspection into three regions. The base is an
elongated stalk, consisting primarily of a six-membered
antiparallel helical coiled-coil (the “core” region of the
protein (Zhao et al., 2000)) composed of the two heptad-
repeat regions, HR-1 and HR-2, previously identified in the
RSV-F sequence (Chambers et al., 1990) and shown to
adopt a six-membered trimeric coiled coil in solution (Law-
less-Delmedico et al., 2000; Matthews et al., 2000).
The head region, approximately the shape of an inverted
triangular prism, has a large central cavity accessible to the
exterior of the protein through a channel down the axis of
the protein and three symmetrically positioned radial chan-
nels. Between these two sections of the protein is an inter-
face described as the neck region. The approximate dimen-
sions of the protein measured from the electron micrographs
(25 to 30 nm in length, Fig. 5C) are in good agreement with
the size of the protein in the homology model. Note in
particular that for most of the structures an electron-dense
center can be seen in the head of the spike that may corre-
spond to the radial channels observed in the model.
As Chen and colleagues noted for NDV-F (see Fig. 7 in
Chen et al., 2001), the structure has obvious implications for a
possible mode of action of RSV-F, wherein the fusion peptides
at the end of HR-1 are sequestered in some undefined manner
within the head of the protein, only to be released when contact
with a target cell triggers the exposure of the fusion peptides
which then bury within the target cell membrane. A rearrange-
ment of the conformation of the F protein then brings the
fusion peptides and viral anchor peptides into close proximity
(as in the fusion-activated homology model presented in Fig.
6), simultaneously resulting in the fusion of the two mem-
branes. In the EM images, aggregation of trimeric units into
rosettes always involved interactions at the base of the stalk.
The RSV-F protein model suggests that this is likely to be a
consequence of hydrophobic interactions between the fusion
domains at the base of the stalk following conformational
reorganization.
Correct identification of the model as representing the
postfusion form of RSV-F is essential if the structure is to
be correctly interpreted. The NDV-F crystal structure was
determined using crystals grown from inactivated F0 protein
(Chen et al., 2001) but the authors are noncommittal on
whether the structure is of F0 or some other form of the
protein that has undergone proteolytic activation. Two ob-
servations in particular suggest that the structure is of post-
fusion protein. First, the NDV-F structure on which it is
based showed well-defined central and radial channels in
which one would expect the fusion peptide to be buried in
the prefusion structure of the protein. The absence of elec-
tron density in these channels, which correspond to the
Fig. 2. Effect of an RSV-F inhibitor on fusion activity in the syncytium formation assay. Cells were transfected with plasmid expressing a codon-optimized
RSV-F construct in the presence of increasing concentrations of VP14637, a known inhibitor of RSV-F activity. (A) Photographs of cells taken 48 h
posttransfection at 400 magnification. Concentration of inhibitor (in ng/ml) is indicated in each photograph. Control cells were transfected with plasmid
lacking the RSV-F construct. In the absence of inhibitor cell death due to syncytium formation is complete, while at high concentrations a degree of
inhibitor-induced cell death occurs. (B) Graph of quantitated syncytium formation at different inhibitor concentrations. Each data point corresponds to one
of the photographs in (A), allowing correlation of the degree of syncytium formation with the experimental score. The drop in absorbance values at high
concentrations of inhibitor correlates with the cell death seen in the photographs.
Table 1
Syncytium formation assay results for a selection of inhibitor resistance
mutantsa
RSV-F construct EC50 (ng/ml)
Compound 1 Compound 2 Compound 3
Wild type 24 97 2100
F488L NI NI 7600
D486N NI ntb 4300
V76A, G446E, N517I 3 8 NI
N517I 18 125 4100
V76A 29 97 3000
G446E 2 9 NI
a Constructs containing the listed mutations were transfected into 292
cells and the level of syncytium formation in the presence of serial dilu-
tions of each inhibitor was determined. EC50 values for each mutant were
calculated from computational fitting of the data to a sigmoidal dose–
response curve. A value of NI indicates no inhibition seen at the highest
concentration of inhibitor tested. The three compounds are (1) VP14637
(Patent WO 99/38508), (2) R170591 (Patent WO 01/00612), and (3)
CL-387626 (Wyde et al., 1998).
b nt, not tested.
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cavities seen in EM images of postfusion RSV-F (Fig. 5C),
suggests that the fusion peptides have been revealed and are no
longer sequestered within the head. Second, the surprisingly
good correlation between the position of the ends of the
NDV-F structure and those of the RSV core structure implies
that the NDV-F protein had formed an equivalent coiled-coil
core region, characteristic of the postfusion form of the protein.
Other lines of evidence, such as the burial of a known antigenic
region of the protein and putative modes of action for two
fusion inhibitors (see below), support the identification of the
structure of the RSV-F model and the NDV-F crystal structure
as the postfusion form of the proteins.
A model of the RSV-F protein based on the NDV-F
crystal structure has previously been published by Smith
and colleagues (2002). This model is based solely on the
NDV-F structure and thus lacks the majority of the helical
coiled coil that constitutes the stalk region of the protein.
Combination of the RSV core and NDV-F structures cir-
cumvents this problem and allows a clearer view of the
entire RSV-F structure. Comparison of the sequence align-
ments used here (Fig. 6B) and by Smith et al. show few
differences and visual inspection of the two models suggests
that the overall structures of those regions common to both
models are very similar.
Fig. 3. Structures of three known RSV-F inhibitors: (1) VP14637 (Patent WO 99/38508), (2) R170591 (Patent WO 01/00612), (3) CL-387626 (Wyde et al.,
1998).
Table 2
EC50 of resistance mutants to three RSV fusion inhibitors identified from virus culture in the presence of the inhibitora
Mutant isolated
(virus strain)
Compound used
for selection
Mean  SD EC50 (ng/ml)
Compound 1 Compound 2 Compound 3
Wt (A2)b None 0.4  0.2 (n  6) 0.8  0.6 (n  6) 414.1  140.9 (n  6)
Wt (Long) None 0.6 0.2 (n  6) 3.0  0.9 (n  6) 186.2  47.4 (n  6)
Wt (B1) None 1.4  0.4 (n  6) 9.9  7.5 (n  6) 80.0  6.9 (n  6)
F488I (A2) 1 10,000 10,000 1698.2
F488L, N517I (A2) 1 10,000 10,000 609.5
D489Y (Long) 1 10,000 10,000 260.7
D489Y (Long) 2 ntc nt nt
D486N (Long) 2 d d d
D486E (B1) 1 d d d
F488V (B1) 1 d d d
V76A, G446E, N517I (A2) 3 nt nt 75,000 5400 (n  2)
a Viruses were cultured in the presence of compounds, the resistant strains isolated, and their F-protein genes sequenced. Cross-reactivity was tested by
the CPE reduction assay in the presence of other compounds. The three compounds are (1) VP14637 (Patent WO 99/38508), (2) R170591 (Patent WO
01/00612), and (3) CL-387626 (Wyde et al., 1998).
b Wt, wild-type RSV A2, Long or B1. Variants are noted by reference to the amino acid substitution coded within the respective F genes.
c nt, not tested.
d Virus titer insufficient for CPE assay.
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Characterization of sites of inhibitor escape mutants
The majority of the mutations identified as resulting in
resistance to compounds 1 and 2 were found to cluster
around F488 (Fig. 7), which fits into a hydrophobic pocket
on the face of the internal helical bundle of the RSV-F core
(Zhao et al., 2000). Equivalent pockets in the coiled-coil
regions of other related fusion proteins, such as HIV gp41,
are well characterized as sites of inhibitory action for both
small molecule (Zhou et al., 2000) and peptidic (Eckert et
al., 1999) inhibitors. Other mutations (e.g., N517I) present
in the F gene of viruses exposed to compounds 1 and 2 were
sometimes found in combination with those adjacent to the
hydrophobic pocket, but in all cases these were shown to
have no influence on inhibitor action when examined indi-
vidually in the syncytium formation assay (Table 1).
A completely different site of mutation was identified for
resistance to compound 3. Selection for resistance to com-
pound 3 resulted in the isolation of a virus bearing three
mutations in the RSV-F sequence: V76A, G446E, and
N517I. Analysis of all eight possible combinations of these
three mutations in the syncytium formation assay demon-
strated that G446E was solely responsible for resistance to
compound 3 although protein carrying this substitution was
less efficient at inducing fusion in the absence of the other
mutations (Table 1). G446 lies on the side of the head
region, surrounded by a cluster of basic residues in our
model (Fig. 7). The introduction of a negatively charged
glutamate at this position may act to reduce the affinity of
Fig. 4. Graph showing the syncytium formation assay results for an RSV-F
construct carrying the mutation F488L. The three curves show the susceptibility of
wild-type F to VP14637, a known inhibitor of RSV-F activity (Œ, EC50 24 ng/ml);
the complete resistance to VP14637 seen for the construct carrying the mutation
F488L (, EC50 unmeasurable); and the continued susceptibility of the F488L
mutant to CL-387626, a less active inhibitor of RSV-F that acts on a different site
than does VP14637 (, EC50 7.6 g/ml). The curve shown for each data set was
calculated by fitting to a sigmoidal dose–response model.
Fig. 5. Recombinant RSV-F protein. (A) Coomassie blue stained SDS–PAGE profile of nonreduced and reduced RSV-F purified from recombinant baculovirus-infected
cultures. Uncleaved F0 and cleaved fragments F1, F1, and F2 are indicated. (B) Schematic representation of the differentially cleaved RSV-F recombinant protein. The two
independent cleavage sites are indicated: site 1 (133RKRR/FLGF140) and site 2 (106RARR/ELPR113). Potential sites of N-linked carbohydrate addition are indicated by
attached circles, and numbers above the two schematics correspond to species identified in the gel profile shown in (A). (C) Electron micrographs of recombinant RSV-F
expressed, secreted, and purified from baculovirus-infected insect cell cultures. Bars t 50 nm (top panel) and 20 nm (bottom panels).
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compound 3, which contains negatively charged sulfonic
acid groups, with the basic residues surrounding the point of
mutation. The role of this cluster of basic residues in the
function of RSV-F is unclear, but there is strong evidence
that RSV-F interacts with heparin or other glycosaminogly-
cans (GAGs) on the cell surface (Martinez and Melero,
2000; Hallak et al., 2000; Karger et al., 2000). It may be that
this interaction is partly mediated by these basic residues
and that compound 3 disrupts the binding to GAG. Inter-
estingly, RSV-F constructs containing the G446E mutation
appear to be slightly more susceptible to inhibition by com-
pounds 1 and 2 than the wild-type protein (Table 1). This
may be a consequence of the reduced levels of syncytium
formation seen for G446E mutants even in the absence of
inhibitor, possibly due to a reduced affinity for target cells.
Antibody binding sites
Antigenic sites on RSV-F have been found to cluster in
immunogenic hotspots (Collins et al., 1996; Lopez et al.,
1996) and the positions of some of these sites investigated
by electron microscopy of RSV-F–antibody complexes
(Calder et al., 2000). Several of these were mapped on the
RSV-F model of Smith and colleagues (2002) and were
shown to be in good agreement with the published EM data.
As expected from the similarities between the model pub-
lished here and that of Smith et al., (2002), the position of
the antigenic sites derived from EM studies of antibody-
bound RSV-F are also in good agreement with our model:
site I (Fig. 8, green) located toward the top of the head, site
II (Fig. 8, red) at the base of the neck, and sites IV, V, and
VI (Fig. 8, blue) overlapping on the side of the head (see
Fig. 4 in Calder et al., 2000). The residues forming site II
have been predicted to form a helix–turn–helix structure
(Lopez et al., 1996; Chambers et al., 1992) and were shown
to do so as a 21-residue peptide in 30% trifluoroethanol
(Toiron et al., 1996). This section of the protein forms a
helix–turn–helix structure in our model that is fully exposed
on the edge of one of the radial channels. If, as hypothe-
sized, the radial channels play a critical role in the function
Fig. 6 (continued)
Fig. 6. (A) Diagrammatic representation of the structure of the homology model of RSV-F. The protein is colored by chain, with the F1 subunits in orange,
green, and violet and the F2 subunits in red, yellow, and blue. The division of the structure into head, neck, and stalk (or core) regions is indicated, as are
the attachment points for the three viral anchor peptides and three fusion peptides, which are not included in the model. (B) Sequence alignment of RSV-F,
the RSV-F core, and NDV-F used for model building. Regions shaded gray in NDV-F were not present in the crystal structure. Regions of the RSV-F
sequence that are shaded blue were modeled on the structure of the RSV-F core rather than on the structure of NDV-F, where it was present. Gray shading
of the RSV-F sequence indicates regions that are absent from the modeled structure.
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of the F protein as entry points for burial of the fusion peptide
in the prefusogenic structure, then the potential impact of
antibody binding immediately adjacent to the channel is clear.
Sites IV, V, and VI are in very close proximity to the site of the
resistance mutation for compound 3, G446E (Fig. 7), suggest-
ing a possible similar mode of action for neutralizing antibod-
ies that bind in this region.
A discrepancy is apparent between the model RSV-F
structure and the predicted location of another immunogenic
region comprising residues 205 to 237 (Fig. 8, orange and
purple). These residues are almost totally concealed within
the neck region of the RSV-F model, with only approxi-
mately 1000 Å2 of a total potential surface of 6500 Å2
exposed. Two overlapping peptides from this region react
with neutralizing sera from RSV-infected animals and in-
duce neutralizing antibodies to RSV (Collins et al., 1996).
All of the surface exposed in the model originates in resi-
dues from the first peptide (residues 205–221, Fig. 8, or-
ange), with residues in the second peptide (222–237, Fig. 8,
purple) completely buried. Residues 205–221 correspond to
a short region where the predicted secondary structures of
NDV-F and RSV-F disagree (Fig. 6B), suggesting a possi-
ble local difference in structure. Nevertheless the sections of
protein that bury these residues, 60–80 in F2 and 468–480
in F1, are in areas of high confidence in the model. This
observation implies that antibodies specific to these regions
interact when the residues are exposed in some different
conformation of RSV-F, such as the pre-fusogenic form of
the protein or an intermediate that appears during the con-
version from the pre- fusogenic to the fusogenic form.
Conclusion
We have described a novel assay for RSV-F function that
allows quantitative measurement of the effect of RSV-F
inhibitors on the induction of cellular fusion and allows
rapid testing of the effect of specific mutations on protein
function without the complication of mutagenesis of the
viral genome. Because this assay correlates well with ex-
perimental data for the inhibition of viral function in vitro,
we have used it to characterize a series of drug escape
mutants isolated using serial passage in the presence of
inhibitors. Three recently described RSV-F-specific fusion
inhibitors were used to select resistant viruses and the point
mutations associated with resistance identified.
We have also shown that the homology model of RSV-F
presented here is supported by experimental evidence in-
cluding gross morphology derived from EM images and the
position and nature of antibody binding sites. The sites
associated with inhibitor resistance were mapped on to the
validated model, allowing the compounds to be grouped
into two classes. Correlation between the location of the
mutations and the model structure has provided hypotheses
for the mechanisms by which the two classes of fusion
inhibitors function. We propose that one class functions by
disrupting the formation of the helical core region of the
protein through binding within or near the hydrophobic
binding pocket in the trimeric core occupied by F488. We
hypothesize that a second class of fusion inhibitor, repre-
sented by compound 3, interacts with a region of basic
residues within the RSV-F head and perturbs F function,
perhaps through interference of F interaction with a cellular
GAG target. A number of neutralizing antibodies that bind
to a site overlapping this region may well act in a similar
manner. It is anticipated that these observations will allow
the continued rational development of new inhibitors of
RSV-F action.
Materials and methods
Cells and virus
HEp-2 cells (American Type Culture Collection
(ATCC), Rockville, MD, USA) were maintained in Eagle’s
minimal essential medium (Biowhittaker, Walkerville, MD,
USA) containing 10% gamma-irradiated fetal bovine serum
(FBS) (Invitrogen New Zealand Ltd, Auckland, New Zea-
land) and 1% L-glutamine (Biowhittaker Walkerville, MD,
USA). RSV A2 (VR-1302) strain, RSV Long (VR-26)
strain, and RSV B-1 (VR-1400) strain were purchased from
ATCC and grown in HEp-2 cells. 293 cells were also
purchased from ATCC.
Recombinant RSV-F constructs, mutagenesis, and
expression studies
Single-stranded synthetic DNA oligonucleotides encod-
ing portions of RSV A2 F glycoprotein incorporating opti-
mal codons (Haas et al., 1996) and without potential
poly(A) addition or splice sites were generated syntheti-
cally. These oligonucleotides, of average length 60 bases,
were annealed and ligated together to produce three frag-
ments: (1) a 631-bp PstI–MfeI fragment, (2) a 606-bp MfeI–
XhoI fragment, and (3) a 379-bp XhoI–BamHI fragment.
The gel-purified fragments were cloned into the pLitmus
vector. The full-length gene was assembled by sequential
cloning into the CMV expression vector pCICO, a deriva-
tive of pJW4304 (kindly provided by J. Mullins, Depart-
ment of Microbiology, University of Washington (Chapman
et al., 1991)), which contains a full-length CMV promoter,
CMV authentic intron sequence, SV40 early region 3 ter-
minator, and SV40 origin of replication. The construct en-
coding the soluble form of the recombinant glycoprotein
lacking sequences encoding the transmembrane and cyto-
plasmic tail domains was titled pCICO.Fopt. A membrane-
anchored full-length F was generated by insertion of a
270-bp EcoRI–XbuI fragment encoding the transmembrane
and cytoplasmic domains of RSV-F into pCICO.Fopt to
yield pCICO.F.FL.opt.
The RSV-F synthetic sequence was designed to include
unique restriction sites approximately every 50 to 100 bases.
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This enabled the use of cassette mutagenesis to rapidly mutate
any region of the molecule. In brief, oligonucleotides contain-
ing the desired mutation were assembled in double-stranded
fragments and cloned into the appropriate restriction sites of
the RSV-F synthetic gene. Mutations were routinely confirmed
by sequencing the replaced region.
Expression levels of F were assayed by transient CaPO4
precipitation-mediated transfection assays in 293 cells. Cells in
a 60-mm dish were transfected with 5 g of plasmid and 0.5
g of pVARNA (Groskreutz and Schenborn, 1994). Expressed
proteins were radiolabeled by incubation for 5 h in the pres-
ence of [35S]methionine and cysteine 24 h posttransfection.
Cell lysates and supernatants were immunoprecipitated with an
RSV-F-specific monoclonal antibody and the precipitates were
analyzed by polyacrylamide gel electrophoresis. Gels were
impregnated with scintillant, dried, and exposed to X-ray film.
Synthetic constructs for codon-optimized RSV-G and
RSV-SH were produced in a similar manner and used for
coexpression studies with the RSV-F construct. Expression
levels of both proteins were assessed by radiolabeling and
immunoprecipitation as for RSV-F above.
Syncytium formation assay
Fusion activity of the RSV-F constructs was measured in
293 cells. Cells in six-well plates (Corning) at approxi-
mately 50% confluency were transfected by adding plasmid
DNA (2 g/well) carrying the constructs of interest in
CaPO4 solution for 4 h followed by a 15% glycerol shock
and then washed with PBS. To each well, 2 ml growth
medium was added and the cells were incubated at 37°C in
a 5% CO2 incubator and observed 24–48 h posttransfec-
tion. The F-transfected cells are identical in appearance to
RSV-F-infected cells, being characterized by the presence
of many large syncytia and dying cells due to the fusion of
cellular membranes by the expressed F protein. Control
cells were confluent at the same time point.
For quantitative assay, transfected cells, after glycerol
shock and wash, were trypsinized and transferred to 96-well
plates containing dilutions of inhibitor. Cells from one well
of a six-well plate were distributed to 30 wells of a 96-well
plate. Syncytium formation was quantified at 48 h posttrans-
fection by addition of 20 l of CellTiter 96 One solution
(Promega) and incubation for 1 to 4 h at 37°C. The color
reaction was then stopped by addition of 25 l 10% SDS to
each well and the difference in absorbance of the well at 492
and 690 nm measured. EC50 values were determined from
the absorbance data by computer curve fitting. Fusion in-
hibitors were assayed by exposing transfected cells to half-
log serial dilutions of inhibitors with the reduction in
scorable syncytium formation used as a direct measurement
of the efficacy of the inhibitor. Results from the F-specific
syncytium formation assay and RSV viral CPE assays were
comparable in both relative potency of inhibitors tested and
the susceptibility of F variants bearing resistance mutations
(Figs. 2 and 4, Table 1).
RSV CPE reduction assay
All test compounds were synthesized by Biota. Serial three-
fold dilutions of test compounds were prepared in 96-well
tissue culture plates containing 100 l per well of assay me-
dium (Eagle’s minimal essential medium (MEM) supple-
mented with 2% fetal bovine serum and glutamine alanyl-L-
glutamine). Human laryngeal carcinoma (HEp-2) cells were
trypsinized and diluted in assay medium to a concentration of
1.5  105 viable cells/ml. One hundred microliters of the
diluted cells was added to each of several individual wells of
each 96-well plate and designated as uninfected control wells.
The remaining cell suspension was infected with RSV at a
multiplicity of infection of 0.2 – 0.05 PFU per cell depending
on virus strain used. The cell–virus suspension was mixed well
by inversion and 100 l was immediately dispensed into the
remaining wells of the 96-well plates. Assay plates were incu-
bated in a 37°C incubator for 5 days. Viral replication was
quantified by determination of cell viability substantially as
described by Watanabe and colleagues (1994). Briefly, 100 l
of 3 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) was added to each well and plates
were incubated at 37°C in a 5% CO2 incubator for 2 h. Wells
were aspirated to dryness and the crystalline product of MTT
metabolism was dissolved by addition of 200 l of 100%
isopropanol. The extent of metabolism was measured via de-
termination of absorbance using a computer-controlled micro-
plate reader at 540 nm with a reference wavelength of 690 nm
(Denizot and Lang, 1986). The 50% effective concentration
(EC50) was determined using computer curve fitting.
Viral plaque assay and selection of drug-resistant virus
HEp-2 cells were seeded at a density of 8  105 cells/
well and grown until fully confluent in six-well plates
(Corning, Acton, MA, USA). Cells were infected with ap-
proximately 2  105 PFU of RSV in the presence of 0.1, 1
or 10 g/ml of compound 1 or 2. After adsorption for 1 h at
37°C the virus inoculum was replaced by an agarose (Sigma
Chemical Co., St Louis, MO, USA) overlay supplemented
with 2% FBS, 1% L-glutamine, and the same concentration
of compound 1 or 2. Plaques were allowed to develop for 3
days. Plaques were picked and expanded in the presence of
compound 1 or 2 in HEp-2 cells at the same concentration
as used initially. Resistant virus to compound 3 was gener-
ated by limit dilution passaging over six passages, with the
drug concentration ranging from an initial 0.25 g/ml to a
final concentration of 2 g/ml. Putative resistant virus (ev-
ident by the presence of viral cytopathology in these cul-
tures) was recovered. RNA isolated, and the F gene se-
quence determined via RT-PCR. Viruses were considered
resistant to an inhibitor if the EC50 value was shifted by at
least 10-fold compared with the co-passaged parental virus.
To test for drug resistance/cross-resistance, larger-scale vi-
rus stocks were grown, titered, F gene resequenced, and
assayed for drug resistance using the assay described above.
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In the case of multiple mutations arising in a putative
resistant virus, the importance of each substitution was
determined by separate assay in the syncytium formation
assay (Mason et al., 2000) described above (see Table 1).
Model building
As a preliminary step in modeling the RSV-F protein a
chimeric construct of the NDV-F structure and the RSV-F
core structure was produced. This chimera was built using
SwissPDB Viewer (SPDBV, Guex and Peitsch, 1997) by
superimposing the coordinates of G184-Q202 of chain A
from the RSV-F core onto G171-Q189 of chain A in the
NDV-F structure. These residues were selected after con-
ducting alignment of the amino acid sequence of the two
proteins from which it was determined that they were struc-
turally equivalent regions. The superimposition revealed an
excellent correspondence in structure, allowing completion
Fig. 7. Structure of RSV-F showing the position of several escape mutants that allow continued RSV-F activity in the presence of three specific fusion
inhibitors: (1) VP14637 (Patent WO 99/38508), (2) R170591 (Patent WO 01/00612), and (3) CL-387626 (Wyde et al., 1998). The residues where escape
mutations for compounds 1 and 2 are found are shown as spheres (D486, D489 red; F488 yellow) on one of the three F2 chains and cluster in the HR-A
helix over a hydrophobic pocket in the surface of the internal HR-B helices of the core domain. For compound 3, resistance mutation arises at a second site
on the head of the RSV-F molecule The central glycine residue (G446, shown in green) gives rise to resistance on mutation to a glutamate. The cluster of
basic residues around the glycine believed to interact with the inhibitor is highlighted (blue).
Fig. 8. Location of several antigenic sites on the RSV-F model structure. The majority of the protein is shown as a gray backbone trace, with residues
contributing to antigenic sites shown as color-coded spheres. Site I is shown in green, Site II in red, and Sites IV, V, and VI, which overlap, in blue. The
correlation between Sites IV, V, and VI and the location of the resistance mutation for compound 3 (Fig. 7) is clear. Two contiguous peptides give rise to
RSV-neutralizing antibodies in animals; residues 205–221 (orange) and 222–237 (purple) are indicated. These residues are almost completely buried in the
RSV-F model, suggesting that they are available for antibody binding in a different conformation of the protein.
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of the chimera by manual editing of the combined PDB
files. The chimeric structure was subject to energy minimi-
zation of the four-residue stretches either side of the six
joining points to remove any minor errors that the manual
combination of structures had introduced. The chimera was
then used as the basis for building a model of RSV-F. Note
that the sequence used for RSV-F corresponds to the RSV
strain A2 clone in use in the Biota Virology Laboratory and
differs in five sites from GenBank Entry AAB59858.1
(E66K, P101Q, P102A, I379V, and M447V). A single loop
(residues A412 to S425 in RSV-F) was not able to be built
in a satisfactory manner using an automated alignment
(CLUSTAL (Thompson et al., 1994)) of the RSV-F and
chimera sequences and was manually adjusted on the basis
of PHD secondary structure prediction (Rost et al., 1994)
and the maintenance of a conserved disulfide bond, with the
final alignment shown in Fig. 6B. The two chains of each
F1–F2 pair were initially modeled as separate entities in
SPDBV, with manual inspection of the candidate loops for
each mismatch used to select the optimal structure. A total
of 10 loop structures were rebuilt (1 in F2 and 9 in F1).
The separate RSV-F1 and RSV-F2 structures were then
combined and the complete trimeric RSV-F structure was
assembled by superimposing on each of the subunits of the
chimera. Minimization of the complete RSV-F model was
carried out with Discover in the InsightII package (Accelrys
Inc., CA, USA) under the cvff forcefield to remove unde-
sirable interactions that had been generated by the modeling
process. First, the residues surrounding each inserted loop
were minimized with the rest of the structure held fixed to
correct any minor mismatches at insertion points. Then the
backbone atoms of the whole protein were held fixed and
the side chain atoms minimized using Steepest Descent
minimization until the maximum gradient value dropped to
below 10. The backbone constraints were then removed and
the whole structure was allowed to minimize for a further
100 steps of Steepest Descent minimization. Superposition
of the final model with the coordinates of the NDV-F
fragment and RSV core structures gave backbone RMSDs
for common residues of 1.03 and 1.37 Å, respectively. The
completed model of RSV-F was assessed using the
Verify3D program (Eisenberg et al., 1997) which showed
that the model was of acceptable quality. More than 93% of
residues in the model had backbone geometry in the favor-
able region of a Ramachandran plot.
Large-scale expression and purification of recombinant
RSV-F
The RSV (A2 strain) F gene was amplified by RT-PCR
with oligonucleotide primers designed to incorporate
BamHI restriction sites for subsequent cloning into the bac-
ulovirus shuttle vector, pAcYM1.his. This vector was de-
rived from pAcYM1 by insertion of an oligonucleotide
fragment encoding a histidine tag into the BamHI site.
Subsequent expression of cloned inserts produced recombi-
nant proteins with a fused C-terminal His tag. The F gene
was amplified to include the N-terminal signal sequence but
was truncated at the C terminus to remove the transmem-
brane and cytoplasmic domains. This vector was cotrans-
fected along with linearized BacPac6 baculoviral DNA into
Spodoptera frugiperda cells. Recombinant baculoviruses
were selected on the basis of F protein secretion into the
culture medium and virus stocks were subsequently pre-
pared. High-titered recombinant virus stocks were used to
infect Hi5 cells in suspension culture and medium harvests
were collected at 48 h postinfection. Harvests were clarified
by centrifugation followed by filtration through 22-nm fil-
ters before concentration and buffer exchange by tangential
flow ultrafiltration. The concentrated preparations were
passed through a Ni2-affinity column (Ni-NTA Agarose,
Qiagen, Germany), the column was washed, and bound
protein was eluted with 100 mM imidazole. Elution frac-
tions containing recombinant F protein were assessed by
SDS–PAGE analysis, pooled, and then concentrated by fil-
tration (Centricon-50). SDS–PAGE analysis revealed that
all preparations comprised a doublet (see Fig. 5A), reflect-
ing incomplete cleavage at the F2/F1 junction as well as at
a second proteolytic activation site originally identified by
us (Mason et al., 2000) and recently also described by others
(Gonzalez-Reyes et al., 2001; Zimmer et al., 2001), at the N
terminus of the RSV-F unique sequence.
Electron microscopy
Recombinant F protein was diluted in phosphate-buf-
fered saline to approximately 10 g/ml. Droplets of approx-
imately 5 l of this solution were applied to thin carbon
films on 400-mesh copper grids which had been glow-
discharged in nitrogen for 30 s. After 1 min the excess
protein solution was drawn off, followed by washing in
approximately 5 l PBS, then 2–3 droplets of 2% uranyl
formate (prepared as described in Russell and Hyder, 1976)
was added for 1 min. The grids were air-dried and then
examined at 80 kV in a JEOL 100B transmission electron
microscope at a magnification of 100,000x. Electron micro-
graphs were recorded on Kodak SO-163 film and developed
in undiluted Kodak D19 developer. The electron-optical
magnification was calibrated by comparison with the width
of tobacco mosaic virus (180Å) imaged under similar con-
ditions (calibration virus was a gift from Adrian Gibbs,
Australian National University).
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